Sedulis' $320 million acquisition of Essen BioScience Inc.

Biotech Channel News: Sedris will buy Essen BioScience for $320 million.
Essen BioScience has achieved high double-digit growth over the past few years, with sales expected to be about $60 million in 2017 and high profitability.
company is headquartered in Ann Arbor, Michigan, USA, with sales entities in the United Kingdom and Japan and currently employs about 150 people.
entered the bioanalysting business through its 2016 acquisition of IntelliCyt, which will significantly expand its bioanalytic business.
with Essen's real-time live cell analysis platform, our lab business has added a key new technology to enhance and accelerate drug development.
," said Joachim Kreuzburg, CEO of Sedollis, "This powerful technology will work with our IntelliCyt business."
, Sedtoris will be able to provide our customers with the broadest range of the industry's most innovative cellular analysis services.
" In rapidly evolving areas such as immuno-oncology, antibody development and stem cell research, innovative analytical methods are key factors in the advancement of science and technology.
more than a decade, Essen BioScience has focused on instruments, software, and reagents for real-time live cell imaging and data analysis.
the technology not only accelerates the development of new drugs, but also provides a new perspective and understanding for pathology research.
excited to join the Sedulis Group and form an industry-leading cell analytics portfolio with IntelliCyt.
this is not only an opportunity to establish Essen's market leadership, but also to continue to develop and introduce more innovative solutions for the life sciences.
addition, we believe that integration with Sedris will provide special opportunities for the continued growth and development of our employees, customers and business partners.
," said Brett Williams, president and ceo of Essen.
will update the 2017 financial guidance of its laboratory business unit, as well as the financial guidance of the Sedtoris Group after the transaction ends.
this report contains a statement regarding the future development of the Sedulis Group, which is based on assumptions and assessments and has certain risks and uncertainties, we do not guarantee that the statement will be true.
about the Sedolis Sedulis Group is the world's leading supplier of pharmaceutical and laboratory equipment, with two business units: The Bio-Process Division and the Laboratory Products and Services Division.
Biotechnology has a broad product portfolio focused on single-use solutions designed to help customers produce safe and effective biotech drugs and vaccines.
Laboratory Products and Services, through its high-quality laboratory instruments, consumables and services, is committed to providing services and meeting the needs of laboratory research, pharmaceutical and biopharmaceutical quality assurance, and academic and research institutions.
founded in 1870, the company has production and sales centers in more than 110 countries around the world.
About Essen BioScience Essen BioScience was founded in 1996 in Ann Arbor, Michigan, USA, and develops and produces instruments, software, reagents, and consumables that help researchers quantify and remotely sense most cell processes in real time.
IncuCyte system is a real-time quantitative live cell analysis platform that enables 24/7 automatic acquisition and analysis imaging in standard laboratory inccubines for real-time visualization and quantification of cell behavior processes.
system helps researchers make timed, fully dynamic measurements of living cells over days and weeks, providing an in-depth understanding of real-time dynamic biological processes.
.